News

Latest News

Sort by:
All
Our story: Letter from Blake Mandell, Co-founder and CEO, to Transcend Investors Read More
Media

Our story: Letter from Blake Mandell, Co-founder and CEO, to Transcend Investors
Transcend Therapeutics announces Series A funding round of $40 million Read More
Press Release

Transcend Therapeutics announces Series A funding round of $40 million
Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity Read More
Publication

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity
Methylone, a rapid-acting entactogen with robust anxiolytic and antidepressant-like activity Read More
Poster Presentation

Methylone, a rapid-acting entactogen with robust anxiolytic and antidepressant-like activity
Methylone in the Treatment of PTSD: A Case Series Read More
Publication

Methylone in the Treatment of PTSD: A Case Series
Naturalistic Clinical Evidence for the Use of Methylone in the Treatment of PTSD: A Case Series Read More
Poster Presentation

Naturalistic Clinical Evidence for the Use of Methylone in the Treatment of PTSD: A Case Series
Methylone with Robust Antidepressant-Like Activity in the Forced Swim Test Read More
Poster Presentation

Methylone with Robust Antidepressant-Like Activity in the Forced Swim Test